FDA
-
-
-
-
-
-
-
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
-
-
-
-
-
-
-
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
-
-
-
-
-
-
-
Tango Therapeutics Reports First Quarter 2025 Financial ResultsĀ and Provides Business Highlights
-
-
-
-
-
-
-
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
-
-
-
-
-
-
-
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
-
-
-
-
-
-
-
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
-
335,173 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


